NCT06024473

Brief Summary

This clinical trial is being conducted to see if brain stimulation and brain training together improves cognitive functioning and mood in older adults diagnosed with Mild Cognitive Impairment (MCI). Brain stimulation will be done using repetitive Transcranial Magnetic Stimulation (rTMS). Brain training will be done using immersive virtual reality cognitive training (iVCT) program. The goals of this clinical trail are as follows:

  • Examine if rTMS+iVCT intervention can improve and sustain objective cognitive functioning in individuals with MCI more than control or rTMS only groups
  • Examine if rTMS+iVCT intervention improves participants mental health symptoms, functional abilities, and quality of life more than control or rTMS only groups
  • Examine the impact of rTMS+iVCT intervention on caregiver burden. Eligible participants will be assigned to a standard treatment (no intervention control) group, rTMS only group of rTMS+iVCT group. All participants will undergo baseline assessment to evaluate their cognitive, emotional, and functional abilities. Those in the rTMS only group will receive rTMS treatments for five days per week for two weeks (total of ten sessions). Those in the rTMS+iVCT group will receive rTMS treatment followed by iVCT training for five days a week for two weeks (total of ten sessions). All participants will then repeat testing 2 weeks and three months after baseline testing to assess for possible treatment related changes and lasting effects.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
3mo left

Started Mar 2024

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress87%
Mar 2024Sep 2026

First Submitted

Initial submission to the registry

August 24, 2023

Completed
13 days until next milestone

First Posted

Study publicly available on registry

September 6, 2023

Completed
7 months until next milestone

Study Start

First participant enrolled

March 31, 2024

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2026

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2026

Expected
Last Updated

February 20, 2025

Status Verified

February 1, 2025

Enrollment Period

2 years

First QC Date

August 24, 2023

Last Update Submit

February 19, 2025

Conditions

Keywords

repetitive Transcranial Magnetic Stimulationimmersive virtual realityNeuropsychiatric SymptomsMild Cognitive Impairment

Outcome Measures

Primary Outcomes (1)

  • Change in Hopkins Verbal Leaning Test Standard Score

    range: \<55 to \>130 - higher score is improvement

    baseline, 2 weeks, 3 months

Secondary Outcomes (2)

  • Change in NPI

    baseline, 2 weeks, 3 months

  • Change in Functional Activities Questionnaire score

    baseline, 2 weeks, 3 months

Study Arms (3)

Standard Treatment

NO INTERVENTION

This arm will be followed without intervention

rTMS

ACTIVE COMPARATOR

This group will be randomized to receive rTMS treatment

Device: rTMS

rTMS+iVCT

EXPERIMENTAL

This group will be randomized to receive rTMS and iVCT treatment

Device: rTMS+iVCT

Interventions

rTMSDEVICE

Transcranial Magnetic Stimulation

rTMS
rTMS+iVCTDEVICE

Transcranial Magnetic Stimulation and immersive virtual reality

rTMS+iVCT

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age 55 and over
  • previous diagnosis of Mild Cognitive Impairment
  • Score of 18 or over on the MoCA during pre-screening procedures.

You may not qualify if:

  • below 55 years old
  • Do not pass the TMS Adult Safety Screening
  • Taking medications known to increase risk of seizure
  • Taking ototoxic medications
  • Those with implanted device
  • History of bipolar disorder
  • History of Tourette's syndrome or presence of motor tics
  • History of seizures/ seizures in first degree relatives
  • History of stroke, aneurysm, or cranial neurosurgery
  • Current alcohol related disorder needing medical treatment
  • History of abnormal electroencephalogram (EEG)
  • History of motion sickness, nausea, vomiting, seizures, or migraine
  • Significant balance/gait impairments/history of falls
  • History of hyperacusis or photophobia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Central Arkansas VA Healthcare system

Little Rock, Arkansas, 72114, United States

RECRUITING

MeSH Terms

Conditions

Cognitive DysfunctionCaregiver Burden

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersStress, PsychologicalBehavioral SymptomsBehavior

Central Study Contacts

Ian Moore, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Masking Details
This is an open label pilot study
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: 10 participants each will be assigned to the standard treatment, rTMS only or rTMS and iVCT groups
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 24, 2023

First Posted

September 6, 2023

Study Start

March 31, 2024

Primary Completion

March 31, 2026

Study Completion (Estimated)

September 1, 2026

Last Updated

February 20, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will not share

To ensure participant confidentiality, the database will not be made available for public access. One year post completion of the funded study or upon acceptance of the data for publication, deidentified data will be made available to interested parties. Raw data from neuropsychological testing will only be provided to qualified researchers (e.g. neuropsychologists) to prevent misrepresentation. All other data gathered related to clinical, medical, mental health, and psychosocial histories (sans confidential identifiers) will be made available by the PI or research mentor for future research. The PI and research mentor will assume responsibility for ensuring that participant confidentiality is maintained. Prior to release of data, investigators will need to consent to a VA supported data sharing agreement.

Locations